

CITATION REPORT

List of articles citing

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

DOI: 10.1097/00045391-200007030-00004

American Journal of Therapeutics, 2000, 7, 159-75.

Source: <https://exaly.com/paper-pdf/31244701/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
155	Pharmacotherapy in congestive heart failure: COX-2 inhibition: a cautionary note in congestive heart failure. 2000 , 6, 272-276		7
154	Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. <i>Drugs</i> , 2000 , 59, 957-961	80.1	194
153	The coxibs, selective inhibitors of cyclooxygenase-2. 2001 , 345, 433-42		1214
152	Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. 2001 , 110 Suppl 3A, 33S-42S		154
151	Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. 2001 , 23, 228-41		125
150	Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. 2001 , 38, 1145-57		58
149	Celecoxib: an NSAID with improved gastrointestinal tolerability. 2001 , 17, 1-5		1
148	Will the promise of the COX-2 selective NSAIDs come to fruition?. 2001 , 17, 6-11		
147	Celecoxib versus diclofenac in the management of osteoarthritis of the knee. <i>Scandinavian Journal of Rheumatology</i> , 2001 , 30, 11-8	1.9	154
146	Antipyretic analgesics. 2001 , 255-271		
145	Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications. <i>American Journal of Therapeutics</i> , 2001 , 8, 81-3	1	6
144	Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. <i>American Journal of Therapeutics</i> , 2001 , 8, 85-95	1	269
143	Cyclooxygenase-2 and antagonists in pain management. 2001 , 14, 527-32		8
142	Spin doctors. 2001 , 7, 139-41		
141	Acute renal dysfunction associated with selective COX-2 inhibitor therapy. 2001 , 33, 609-11		14
140	The clinical developments and future of the COX-2 inhibitor drugs. <i>Inflammopharmacology</i> , 2001 , 9, 91-99	1	2
139	Renal effects of COX-2-selective inhibitors. 2001 , 21, 1-15		206

138	Klinische Studien zum selektiven Cyclooxygenase-2-Inhibitor Celecoxib. 2001 , 26, 75-81		2
137	The coxibs, selective inhibitors of cyclooxygenase-2. 2001 , 345, 1708-9		6
136	COX-2 inhibitors compared and contrasted. 2001 , 2, 1859-76		11
135	High blood pressure in the geriatric population: treatment considerations. 2002 , 11, 223-32		20
134	Cyclooxygenase-2--10 years later. 2002 , 300, 367-75		395
133	[Are COX-2 inhibitors a risk factor for cardiovascular disease?]. 2002 , 127, 156-9		1
132	Areas of emerging interest in analgesia: cardiovascular complications. <i>American Journal of Therapeutics</i> , 2002 , 9, 259-69	1	18
131	Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?. 2002 , 14, 225-30		18
130	Recent developments in toxic nephropathy. 2002 , 11, 155-63		12
129	HYALURONAN AND HYLAN IN THE TREATMENT OF OSTEOARTHRITIS. 2002 , 467-481		4
128	Anti-inflammatory and antipyretic analgesics and drugs used in gout. 2002 , 25, 126-138		
127	Rheumatoid arthritis: developing pharmacological therapies. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 927-35	5.9	7
126	Nephrotic syndrome and interstitial nephritis associated with celecoxib. 2002 , 40, 1086-90		53
125	Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. 2002 , 25, 165-72		20
124	Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?. <i>Expert Opinion on Drug Safety</i> , 2002 , 1, 45-52	4.1	9
123	Pharmacology of cyclooxygenase-2 inhibition in the kidney. 2002 , 61, 1210-9		60
122	Viscosupplementation in the olderpatient with osteoarthritis. 2002 , 12, 124-130		
121	[Are COX-2 inhibitors indicated for patients at risk?]. 2002 , 29, 230-2		1

120	Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. <i>American Journal of Cardiology</i> , 2002 , 90, 959-63	3	264
119	Advances with analgesics and NSAIDs for the treatment of spinal disorders. 2002 , 16, 105-21		1
118	The promise of coxibs: how far have we progressed?. 2002 , 23, S1-4		3
117	Renal effects of cyclooxygenase-2-selective inhibitors. 2002 , 23, S15-20; discussion S21-3		43
116	Update of ACR guidelines for osteoarthritis: role of the coxibs. 2002 , 23, S24-30; discussion S31-4		80
115	Commentary. 2002 , 23, S31-S34		2
114	The demographics of chronic pain management. 2002 , 24, S10-7		1
113	Is there a place for non-selective NSAIDs in the treatment of arthritis?. 2002 , 69, 4-7		6
112	Les anti-inflammatoires non stéroïdiens non spécifiques de la COX-2 ont-ils encore une place dans le traitement des maladies articulaires ?. 2002 , 69, 4-7		3
111	The management of persistent pain in older persons. 2002 , 50, S205-24		832
110	A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. 2002 , 54, 522-7		7
109	Renal effects of cyclo-oxygenase-2 inhibition. 2002 , 7, 281-286		4
108	Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. 2003 , 18, 279-91		22
107	Does cyclooxygenase-2 affect blood pressure?. 2003 , 5, 87-92		18
106	A critical appraisal of COX-2 selective inhibition and analgesia: how good so far?. 2003 , 3, 201-17		1
105	Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. 2003 , 169, 2352-9		69
104	[Association between non-steroid antiinflammatory drugs intake and decompensation of heart failure]. 2003 , 120, 658-60		3
103	Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. 2003 , 26, 913-24		15

102	Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer. 2003 , 62 Suppl 1, 102-18	7
101	The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. 2003 , 25, 139-49	17
100	Cancer and the Cyclo-Oxygenase Enzyme. 2003 , 2, 27-55	11
99	Clinical Nephrotoxins. 2003 ,	6
98	Effect of cyclooxygenase-2 inhibitors on blood pressure. 2003 , 37, 442-6	10
97	Cyclooxygenase-2 biology. 2003 , 9, 2177-90	176
96	Audit of Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drug Use in Rural General Practice. 2003 , 33, 70-73	1
95	AdvertisersPIndex. 2003 , 33, 73-73	
94	Pharmacology of COX-2 inhibitors. 2003 , 37, 25-51	3
93	Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. 2003 , 37, 210-42	7
92	Acute congestive heart failure induced by rofecoxib. 2004 , 17, 131-5	5
91	Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. 2004 , 10, 3908-18	51
90	Effects on the kidney: role of COX-2 inhibitors. 2004 , 179-194	
89	Cyclooxygenases, the kidney, and hypertension. 2004 , 43, 525-30	133
88	Renal cyclooxygenase-2 (COX-2). Physiological, pathophysiological, and clinical implications. 2004 , 27, 43-62	27
87	Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. 2004 , 19, 1149-53	31
86	COX-2 Inhibitors. 2004 ,	4
85	Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. 2004 , 43, 573-7	58

84	Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study. 2004 , 60, 489-501		10
83	Therapeutic strategies for rheumatoid arthritis. 2004 , 350, 2591-602		416
82	Papel de los inhibidores selectivos de la COX-2 en la hipertensi3n arterial. 2004 , 21, 30-37		
81	Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. 2004 , 26, 70-83		50
80	Dosing of antirheumatic drugs in renal disease and dialysis. 2004 , 10, 190-204		10
79	Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. <i>American Journal of Therapeutics</i> , 2004 , 11, 124-9	1	48
78	Perspectives and Clinical Significance of Eicosanoids in Pain and Inflammation. 319-325		
77	Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (Review). 2005 , 13, 559		42
76	The Nonsurgical Management of Spinal Pain in the Elderly: NSAIDs, Opioids, and Epidural Steroid Injections. 2005 , 17, 144-157		
75	Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. 2005 , 34, 668-77		22
74	Cyclooxygenase-2: a therapeutic target for prostate cancer. 2005 , 4, 203-11		12
73	[Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?]. 2005 , 94, 1851-8		1
72	The safety of rofecoxib. <i>Expert Opinion on Drug Safety</i> , 2005 , 4, 491-9	4.1	29
71	Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney. 2005 , 288, R1767-73		30
70	Nephrotoxicity Related to New Therapeutic Compounds. 2005 , 27, 329-333		8
69	Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. 2005 , 11, 1795-804		106
68	Hipertensi3n arterial en las enfermedades autoinmunes y sist3micas. 2005 , 22, 21-31		2
67	Hipertensi3n arterial en las enfermedades autoinmunes y sist3micas. 2005 , 22, 21-31		

66	Basic pharmacology and advances in emergency medicine. 2005 , 23, 433-65, ix-x		7
65	Nephrotoxicity Related to New Therapeutic Compounds. 2005 , 27, 329-333		20
64	Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in the Netherlands. 2005 , 25, 785-802		7
63	Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. 2005 , 7, R644-65		167
62	[What do we know about the cardiovascular toxicity of the NSAIDs?]. 2006 , 35 Suppl 1, 11-23		3
61	Analgesic efficacy of perioperative celecoxib in ambulatory arthroscopic knee surgery: a double-blind, placebo-controlled study. 2006 , 22, 635-42		53
60	A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. 2006 , 28, 204-21		7
59	Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial. <i>American Journal of Therapeutics</i> , 2006 , 13, 229-35	1	11
58	COX-2 and the kidney. 2006 , 47 Suppl 1, S37-42		98
57	Antinociception and the new COX inhibitors: research approaches and clinical perspectives. 2003 , 9, 227-52		28
56	Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. 2006 , 70, 1495-502		39
55	Nonnarcotic analgesics and hypertension. <i>American Journal of Cardiology</i> , 2006 , 97, 10-6	3	64
54	Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. <i>Cancer</i> , 2006 , 106, 566-75	6.4	50
53	Antipyretic analgesics: nonsteroidal antiinflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolinones. <i>Handbook of Experimental Pharmacology</i> , 2007 , 65-93	3.2	31
52	Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, F542-9	4.3	62
51	Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. <i>Circulation Research</i> , 2006 , 99, 1243-51	15.7	91
50	Update on cyclooxygenase-2 inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 236-45	6.9	51
49	Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. <i>American Journal of Therapeutics</i> , 2007 , 14, 3-12	1	14

48	Celecoxib: a review of its use in the management of arthritis and acute pain. <i>Drugs</i> , 2007 , 67, 2433-72	12.1	67
47	Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 552-60; quiz 1 p following 589		35
46	Use of nonsteroidal anti inflammatory drugs in preterm, term neonates and infants: analgesia by consensus?. <i>Paediatric Anaesthesia</i> , 2007 , 17, 915-7	1.8	
45	Chemopreventive effect of celecoxib in gastric cancer. <i>Inflammopharmacology</i> , 2007 , 15, 1-4	5.1	22
44	Non-steroidal anti-inflammatory drugs. 2008 , 419-457		2
43	Celecoxib and ankylosing spondylitis. <i>Expert Review of Clinical Immunology</i> , 2008 , 4, 339-49	5.1	
42	Renal adverse effects of nonsteroidal anti-inflammatory drugs. <i>Expert Opinion on Drug Safety</i> , 2009 , 8, 669-81	4.1	169
41	A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. <i>Scandinavian Journal of Rheumatology</i> , 2009 , 38, 133-43	1.9	22
40	Celecoxib in the Treatment of Osteoarthritis. <i>Clinical Medicine Insights Therapeutics</i> , 2010 , 2, CMT.S1967	0	0
39	Topical nonsteroidal anti-inflammatory drugs for osteoarthritis. <i>Postgraduate Medicine</i> , 2010 , 122, 98-106	7	25
38	Rheumatoid arthritis: a new challenge in coming era. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010 , 10, 98-107	2	6
37	Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. <i>The Cochrane Library</i> , 2011 , CD008952	5.2	13
36	Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. <i>Drugs</i> , 2011 , 71, 2457-89	12.1	141
35	Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis. <i>Journal of Toxicology</i> , 2011 , 2011, 862153	3.1	12
34	Minimizing cardiovascular complications during the treatment of osteoarthritis. <i>American Journal of Therapeutics</i> , 2011 , 18, 466-76	1	1
33	Eicosanoids and tumor necrosis factor-alpha in the kidney. <i>Prostaglandins and Other Lipid Mediators</i> , 2012 , 98, 101-6	3.7	10
32	Mitigating the cardiovascular and renal effects of NSAIDs. <i>Pain Medicine</i> , 2013 , 14 Suppl 1, S23-8	2.8	34
31	Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013 , 16, 821-47	24	364

30	Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. <i>PLoS ONE</i> , 2014 , 9, e101902	3.7	83
29	COX-2 inhibitors (coxibs). 2016 , 738-762		0
28	Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma. <i>Toxicology</i> , 2016 , 359-360, 71-5	4.4	22
27	Adverse Effects of Nonsteroidal Anti-inflammatory Drugs on the Cardiovascular System. 2016 , 61-89		1
26	Drug-Induced Hypertension in Chronic Kidney Disease. 2016 , 261-298		
25	Endoplasmic reticulum stress eIF2 β /ATF4 pathway-mediated cyclooxygenase-2 induction regulates cadmium-induced autophagy in kidney. <i>Cell Death and Disease</i> , 2016 , 7, e2251	9.8	57
24	Antidiuretic Action of Collecting Duct (Pro)Renin Receptor Downstream of Vasopressin and PGE2 Receptor EP4. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 3022-3034	12.7	53
23	Celecoxib for the treatment of atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 619-335.9		11
22	Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. <i>Pharmaceutical Biology</i> , 2017 , 55, 1295-1303	3.8	22
21	Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. <i>BMC Nephrology</i> , 2017 , 18, 256	2.7	99
20	Regulation and function of renal medullary cyclooxygenase-2 during high salt loading. <i>Frontiers in Bioscience - Landmark</i> , 2017 , 22, 128-136	2.8	9
19	Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. <i>Postgraduate Medicine</i> , 2018 , 130, 55-71	3.7	35
18	Celecoxib suppresses cutaneous squamous-cell carcinoma cell migration via inhibition of SDF1-induced endocytosis of CXCR4. <i>OncoTargets and Therapy</i> , 2018 , 11, 8063-8071	4.4	5
17	Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. <i>BMJ Open</i> , 2020 , 10, e036748	3	6
16	Different Chemical Structures and Physiological/Pathological Roles of Cyclooxygenases. <i>Rambam Maimonides Medical Journal</i> , 2021 , 12,	1.8	2
15	Non-steroidal anti-inflammatory drugs. 2003 , 279-306		4
14	The choreography of cyclooxygenases in the kidney. <i>Journal of Clinical Investigation</i> , 2002 , 110, 33-34	15.9	20
13	COX-2 inhibitors. 2006 , 1000-1015		

12	Antihypertensive therapy in patients, receiving non-steroid antiinflammatory medications. <i>Arterial Hypertension (Russian Federation)</i> , 2006 , 12, 377-379	0.7	
11	Sodium Balance in Heart Failure. 2007 , 351-364		
10	Nonsteroidal Antiinflammatory Drugs. 2008 , 113-128		
9	ADVERSE CARDIOVASCULAR EFFECTS OF NON-CARDIOVASCULAR DRUGS. 2009 , 557-820		
8	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs). 2010 , 223-369		
7	Treatment Options for Degenerative Joint Disease of the Knee. <i>Athletic Training & Sports Health Care</i> , 2011 , 3, 131-139	0.6	
6	Effect of Organic Anion Transporters on the Development of Nephrotoxicity in the Context of NSAIDs Use. <i>Safety and Risk of Pharmacotherapy</i> , 2020 , 8, 198-204	1.2	
5	Comparison of the adverse renal effects of different types of NSAID based on COX inhibition in patients with headaches. <i>Makedonsko Farmaceutski Bilten</i> , 2020 , 66, 55-63	0.1	
4	The choreography of cyclooxygenases in the kidney. <i>Journal of Clinical Investigation</i> , 2002 , 110, 33-4	15.9	9
3	Cardiorenal Risk of Celecoxib compared to Naproxen, or Ibuprofen in Arthritis Patients: Insights from the PRECISION trial.. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022 ,	6.4	1
2	A Comprehensive Review of Celecoxib Oral Solution for the Acute Treatment of Migraine. <i>Health Psychology Research</i> ,		
1	Toxic Nephropathies. 2022 , 311-327		0